C Mater. Cheng, J. Surface functionalized gold nanoparticles for drug delivery. Cheow, W. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids Surf. B Biointerfaces 85, — Chintamani, Singh, J. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer—a prospective clinical study.
World J. Choi, K. Choi, S. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Cirillo, G. Materials Colapicchioni, V. Killing cancer cells using nanotechnology: novel poly I:C loaded liposome-silica hybrid nanoparticles. B 3, — Cortes, J. Nanoparticle albumin-bound nab TM -paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer.
EJC Suppl. Cui, Y. Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin. Acta Pharmacol. Cun, X. ACS Appl. Interfaces 11, — Cuvier, C. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Dadwal, A. Nanoparticles as carriers for drug delivery in cancer. Cells Nanomed. Danhier, F. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
Control Release , — Davis, M. Decuzzi, P. Intravascular delivery of particulate systems: does geometry really matter? Dehaini, D. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Desgrosellier, J.
Integrins in cancer: biological implications and therapeutic opportunities. Cancer 10, 9— Devalapally, H. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer.
Cancer , — Dienst, A. Specific occlusion of murine and human tumor vasculature by VCAMtargeted recombinant fusion proteins. Cancer Inst. Eloy, J.
B Biointerfaces , 74— Fan, L. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 31, — Fang, R. Cell Membrane Coating Nanotechnology. Farokhzad, O.
Impact of nanotechnology on drug delivery. ACS Nano 3, 16— Fontana, F. Wiley Interdiscip. Gao, F. Geisberg, C. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Guo, Y. ACS Nano 9, — Hajizadeh, F. Han, B. Han, G. Functionalized gold nanoparticles for drug delivery. Nanomedicine 2, — He, J.
Nanoscale Res. Hood, J. Tumor regression by targeted gene delivery to the neovasculature. Science , — Hoopes, P. Hypo-fractionated radiation, magnetic nanoparticle hyperthermia and a viral immunotherapy treatment of spontaneous canine cancer. SPIE Int. Hrkach, J. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
Hu, C. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Hu, Y. Engineering the lipid layer of lipid-PLGA hybrid nanoparticles for enhanced in vitro cellular uptake and improved stability.
Acta Biomater. Hua, S. The use of lipid-based nanocarriers for targeted pain therapies. Iwase, Y. Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma. Jain, R. Barriers to drug delivery in solid tumors. Jiang, Q. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. Biomaterials , — Jiang, Y. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems.
Jing, X. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Cancer Kalyane, D. Employment of enhanced permeability and retention effect EPR : nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Kamaly, N. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Khiste, S. Ceramide-rubusoside nanomicelles, a potential therapeutic approach to target cancers carrying p53 missense mutations.
Cancer Ther. Kipp, J. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs.
Kong, F. Kundu, M. Legge, C. Targeted magnetic nanoparticle hyperthermia for the treatment of oral cancer. Oral Pathol.
Lei, W. Polydopamine-coated mesoporous silica nanoparticles for multi-responsive drug delivery and combined chemo-photothermal therapy. Cell-sized liposomes that mimic cell motility and the cell cortex. Methods Cell Biol. Li, W. Tailoring porous silicon for biomedical applications: from drug delivery to cancer immunotherapy.
Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies.
Drug Resist. Li, Y. Lia, N. Selective matrix metalloproteinase inhibitors for cancer. Lim, E. Recent advances in pH-sensitive polymeric nanoparticles for smart drug delivery in cancer therapy. Drug Targets 19, — Litman, T. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter. Cell Sci. Liu, C. Cancer cell membrane-cloaked mesoporous silica nanoparticles with a pH-sensitive gatekeeper for cancer treatment.
B Biointerfaces , — Liu, L. Dihydroartemisinin and transferrin dual-dressed nano-graphene oxide for a pH-triggered chemotherapy. Biomaterials 62, 35— Long, Q. Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine 14, — Low, P. Folate-targeted therapeutic and imaging agents for cancer. Luan, X. A tumor vascular-targeted interlocking trimodal nanosystem that induces and exploits hypoxia. Luo, E.
The toxicity and pharmacokinetics of carbon nanotubes as an effective drug carrier. Drug Metab. Madani, S. A new era of cancer treatment: carbon nanotubes as drug delivery tools. Maeda, H. The enhanced permeability and retention EPR effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.
Enzyme Regul. Mandriota, G. Design and application of cisplatin-loaded magnetic nanoparticle clusters for smart chemotherapy. Mansour, A. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Meng, H. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng, J. Minko, T. Drug targeting to the colon with lectins and neoglycoconjugates. Misra, R. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov. Today 15, — Coformulation of doxorubicin and curcumin in poly D,L-lactide-co-glycolide nanoparticles suppresses the development of multidrug resistance in K cells. Mottaghitalab, F. New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment.
Murakami, M. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Muralidharan, R. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. Najafi-Hajivar, S. Overview on experimental models of interactions between nanoparticles and the immune system.
Nanjwade, B. Dendrimers: emerging polymers for drug-delivery systems. Navarro, G. Nanomedicine 7, 65— Nicholson, R. EGFR and cancer prognosis. Cancer 37 Suppl. Nisato, R. Angiogenesis 6, — Obaid, G. Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles.
Orleth, A. Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy. Drug Target 24, 80— Palazzolo, S. The clinical translation of organic nanomaterials for cancer therapy: a focus on polymeric nanoparticles, micelles, liposomes and exosomes.
Pan, H. Programmable nanoparticle functionalization for in vivo targeting. Park, H. Multifunctional nanoparticles for combined doxorubicin and photothermal treatments. ACS Nano 3, — Parodi, A. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.
Patil, Y. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.
Paulis, L. Dendritic cell-based nanovaccines for cancer immunotherapy. Pelicano, H. Glycolysis inhibition for anticancer treatment. Oncogene 25, — Perica, K. Nanoscale artificial antigen presenting cells for T cell immunotherapy.
Nanomedicine 10, — Perrault, S. Mediating tumor targeting efficiency of nanoparticles through design. Likewise, dose limiting toxicity is significant with nonspecific toxicity to healthy cells, hair loss, loss of appetite, peripheral neuropathy and diarrhea being typical side effects.
The emergence of Multidrug resistance MDR also presents s a significant challenge for the successful treatment of cancer whereby cancer cells become cross resistant to many of the chemotherapeutic agents used. Nanotechnology presents a new frontier for cancer treatment.
It holds potential in minimizing systemic toxicity through the development of functionalized particles for targeted treatment. They also provide an alternative strategy to circumvent multidrug resistance as they have a capacity to by-pass the drug efflux mechanism associated with this phenotype. Scientists most commonly use gold, titanium dioxide, silver, and silicon dioxide, among others, for therapeutic purposes.
However, new research — the results of which now appear in the journal Nature Nanotechnology — suggests that these nanomaterials could facilitate the spread of cancer cells by increasing the gap between blood vessel cells and allowing cancer cells to migrate more easily to new sites. Researchers at the National University of Singapore NUS near Clementi reached this conclusion after studying several models of breast cancer in rodents.
In their paper, they also suggest new ways in which drug developers could use this discovery to devise more effective therapies for cancer and other conditions. Peng and team found that NanoEL speeds up the movement of cancer cells from the original tumor site to new sites and helps the cancer cells that are already in motion evade blood circulation.
Nanoparticles may often be present in processed food and cosmetic products such as creams and lotions. The study authors also explain that we could harness the same mechanism that might represent a vulnerability in cancer treatment and drive tumor spread to achieve precisely the opposite effect. Making blood vessels leakier, they say, may also facilitate the access of chemotherapy drugs or stem cells to damaged tissues.
In addition to cancer, it may also be possible to apply the findings to other conditions that involve damaged organs and tissues. Chemotherapy can be an effective way of treating cancer.
However, while it destroys cancer cells, it can also have adverse effects.
0コメント